Core Viewpoint - Cellectis S.A. shares declined significantly following a favorable arbitration outcome for Allogene Therapeutics, which confirmed Allogene's control over the CAR-T therapy cema-cel and its path to global commercialization rights from Servier [1][4]. Group 1: Legal Outcome and Implications - The arbitration tribunal ruled in favor of Allogene, rejecting Cellectis's claims regarding Servier's development obligations and financial claims related to milestone payments [4]. - The tribunal ordered a partial termination of the license concerning the UCART19 V1 product, directing Cellectis to negotiate a direct license with Allogene under similar terms if Allogene chooses to pursue it [4]. Group 2: Market Reaction - Following the arbitration news, Cellectis's stock fell by 17.35% to $3.96, while Allogene's stock rose by 1.37% to $1.49 [3]. Group 3: Future Developments - Allogene is entering a critical period in the allogeneic CAR T field, with an interim futility analysis scheduled for the first half of 2026, which will compare MRD conversion with cema-cel against standard treatment in first-line patients with large B-cell lymphoma [2].

Core Insights - Cellectis announced a decision from the Arbitral Tribunal regarding its arbitration with Servier related to the License Agreement established on March 6, 2019 [1][2] - The Tribunal partially terminated the License Agreement concerning product UCART19 V1 and mandated Cellectis to engage in discussions for a direct license at Allogene's request [2] Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing cell and gene therapies using its gene-editing platform [3] - The company specializes in allogeneic CAR T immunotherapies, aiming to provide off-the-shelf gene-edited CAR T-cells for cancer treatment [3] - Cellectis maintains in-house manufacturing capabilities, positioning itself as a comprehensive player in the gene editing value chain [3] Company Locations and Listings - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC [4] - The company is publicly traded on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS [4]